Yarrow Bioscience, Inc 8-K, filed Nov 4, 2021
Yarrow Bioscience, Inc. (YARW)
About this 8-K
Yarrow Bioscience, Inc filed this 8-K on November 4, 2021.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
(Address of principal executive offices, including Zip Code)
(
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events.
On November 4, 2021, VYNE Therapeutics Inc. issued a press release entitled “Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is being filed herewith.
| Exhibit No. | Description | |||
| 99.1 | Press Release, dated November 4, 2021. | |||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VYNE THERAPEUTICS INC. | ||
| Date: November 4, 2021 | By: | /s/ Mutya Harsch |
|
Mutya Harsch Chief Legal Officer and General Counsel | ||
Exhibit 99.1
Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study
Results support continued progression of VYN201 development program for autoimmune skin diseases
BRIDGEWATER, N.J., November 4, 2021 -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced preclinical data from a validated animal study showing that its bromodomain and extra-terminal (“BET”) inhibitor, VYN201, demonstrated improvements in reducing fibrotic tissue mass and overall skin repair outcomes with no negative impact on healing time.
VYNE is evaluating its lead BET inhibitor, VYN201, for several autoimmune skin diseases that are characterized by lesions, such as chronic ulcers and blisters, which are challenging to treat and can potentially lead to severe infections and surgical intervention. Frequently used treatments for neutrophilic dermatoses are known to significantly delay the healing of lesions1 and, in this context, VYNE conducted a validated preclinical study to evaluate the effect of VYN201 on skin healing and repair.
In the preclinical study, duplicate identical skin incisions were induced on the flanks of hairless mice under anesthesia. The animals were topically dosed once daily with either 100mg VYN201 vehicle, VYN201 1%, or a hydroalcoholic gel (a negative control known to delay healing) until each lesion had completely healed.
Key findings from the study:
| · | As early as treatment day 5, and consistent with the vehicle control, animals treated with VYN201 1% had a statistically significant decrease (improvement) in global external lesion severity score, a comprehensive evaluation of length, width, swelling and visibility of lesions, compared to those treated with hydroalcoholic gel. |
| · | Consistent with the vehicle control, lesions treated with VYN201 1% completely healed (mean time to heal: 15.5 days) approximately 5 days earlier compared to those treated with hydroalcoholic gel (mean time to heal: 21 days). |
| · | Animals treated with VYN201 1% had a significantly lower global internal lesion severity score than those treated with VYN201 vehicle or hydroalcoholic gel, indicative of an improved internal lesion outcome and a positive effect on reducing the formation of fibrotic tissue mass in the lesion bed. |
| · | By the end of treatment, healed lesions treated with VYN201 1% appeared less visually distinct and more macular in nature with an improved overall aesthetic outcome compared to the other treatments. |
| · | VYN201 vehicle and VYN201 1% appeared to be well-tolerated both within the lesion sites, based on the absence of irritation, and in general throughout the treatment period. |
“We were pleased to learn from this study that VYN201 does not appear to delay skin healing time during treatment or negatively influence skin repair mechanisms,” said Dr. Iain Stuart, Chief Scientific Officer of VYNE. “An additional encouraging outcome from this study was that VYN201 1% treatment, when compared to controls, resulted in less fibrotic tissue being formed in the lesion bed, making the scar much flatter, resulting in an improved overall scar appearance. These findings support the continued progression of this development program, and we look forward to providing additional updates in the future.”
About Bromodomain and Extra-Terminal Domain (BET) Inhibitors
BET proteins play a key role in regulating gene transcription via epigenetic interactions (“reading”), and recent research has determined a key role for these BET proteins in regulating B cell and T cell activation and subsequent inflammatory processes. As epigenetic readers, BET proteins regulate the recruitment of transcriptional factors that are key to the production of several pro-inflammatory cytokines. Inhibiting BET proteins blocks cytokine transcription and therefore may have significant therapeutic potential across a wide variety of immuno-inflammatory/fibrotic and myeloproliferative neoplastic disorders. A topically applied BET inhibitor product has the possibility to positively impact diseases involving multiple, diverse inflammatory cell signaling pathways that are active in rare neutrophilic dermatoses. Furthermore, bromodomain 2 selective oral BET inhibitors may present as more conveniently-administered non-biologic treatment options for both acute control and chronic management of immuno-inflammatory indications, where the damaging effects of unrestricted inflammatory signaling activity is common.
| 1. | Guo S and Dipietro LA, J Dent Res 2010 89(3):219-229 |
About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. VYNE is working to develop and commercialize a variety of therapies for major immuno-inflammatory conditions and rare skin diseases with high unmet medical need. The Company’s unique and proprietary pipeline includes FMX114 for the potential treatment of mild-to-moderate atopic dermatitis and access to a library of bromodomain & extra-terminal (BET) domain inhibitors in both topical and oral forms for the potential treatment of major immuno-inflammatory conditions and rare skin diseases.
For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
Investor Relations:
Joseph Ranieri
LifeSci Advisors, LLC
617-430-7582
joer@lifesciadvisors.com
Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com
Cautionary Statement Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including,
but not limited to, statements regarding the development of VYNE’s product candidate, VYN201, and other statements regarding the
future expectations, plans and prospects of VYNE. All statements in this press release which are not historical facts are forward-looking
statements. Any forward-looking statements are based on VYNE’s current knowledge and its present beliefs and expectations regarding
possible future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and
adversely from those set forth or implied by such forward-looking statements. These risks and uncertainties include, but are not limited
to: the outcome and cost of preclinical and clinical trials for current and future product candidates; determination by the FDA that results
from VYNE’s preclinical and clinical trials are not sufficient to support registration or marketing approval of product candidates;
adverse events associated with the development of VYN201 or VYNE’s approved products; the COVID-19 pandemic and its impact on our
business operations and liquidity including our ability to progress a preclinical or clinical trial; the potential patient base and commercial
potential of VYN201 or any of VYNE’s other product candidates; VYNE’s ability to exercise its option with respect to an oral
BET inhibitor candidate under the terms of the Evaluation and Option Agreement with In4Derm Limited; risks of potential litigation by
third-parties regarding infringement of third-party intellectual property; risks that VYNE’s intellectual property rights, such
as patents, may fail to provide adequate protection, may be challenged and one or more claims may be revoked or interpreted narrowly or
will not be infringed; risks that any of VYNE’s patents may be held to be narrowed, invalid or unenforceable or one or more of VYNE’s
patent applications may not be granted and potential competitors may also seek to design around VYNE’s granted patents or patent
applications; additional competition in the markets in which we compete; inability to raise additional capital on favorable terms or at
all; VYNE’s ability to recruit and retain key employees; and VYNE’s ability to stay in compliance with applicable laws, rules and
regulations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause VYNE’s actual
results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in VYNE’s
Annual Report on Form 10-K for the year ended December 31, 2020, as well as discussions of potential risks, uncertainties, and
other important factors in VYNE’s subsequent filings with the U.S. Securities and Exchange Commission. Although VYNE believes these
forward-looking statements are reasonable, they speak only as of the date of this announcement and VYNE undertakes no obligation to update
publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Given these
risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events.